Variable

n (%) = 34,444

Treatment Cohort

Lumpectomy Alone

4,768 (13.8)

Local Therapy

15,446 (44.8)

Local therapy + Hormone

14,230 (41.3)

Age (quartile)

> = 23, < = 51

9,428 (27.4)

> 51, < = 59

8,059 (23.4)

> 59, < = 68

8,894 (25.8)

> 68, < = 90

8,063 (23.4)

Race

White

28,384 (82.4)

Black

4,249 (12.3)

Other/Unknown

1,811 (5.3)

Charlson-Deyo Score

0

29.747 (86.4)

1

3,975 (12.3)

2+

722 (2.1)

Facility Type

Community Cancer Program/Other

3,171 (9.4)

Comprehensive Community Cancer Program

16,961 (50.3)

Academic/Research Program

9,043 (26.8)

Integrated Network Cancer Program

4,544 (13.5)

Missing

725

Primary Payor

Not Insured/Unknown

914 (2.7)

Private

20.757 (60.3)

Medicaid/Other Government

1,822 (5.3)

Medicare

10,951 (31.8)

Year of Dx

> = 2004, < = 2008

11,027 (32.0)

> 2008, < = 2010

11,320 (32.9)

> 2010, < = 2012

6,021 (17.5)

> 2012, < = 2013

6,076 (17.6)

Histology

Ductal

25,358 (73.6)

Comedocarcinoma

6,130 (17.8)

Papillary

1,082 (3.1)

Ductal + lobular

1,874 (5.4)

Hormonal Status

ER/PR +

5,783 (16.8)

ER/PR -

28,661 (83.2)

HER-2 Status

Negative

2317 (6.7)

Positive

1258 (3.7)

Unknown

30,869 (89.6)

Grade

Well Differentiated

3,497 (10.2)

Moderately Differentiated

9,870 (28.7)

Poorly Differentiated/Undifferentiated

14,005 (40.7)

Cell Type Not Determined

7.072 (20.5)

Tumor Size (quartile) (cm)

> = 0.1, < = 0.5

7,144 (20.7)

> 0.5, < = 1

5,957 (17.3)

> 1, < = 1.9

5,695 (16.5)

> 1.9, < = 98.8

6,218 (18.1)

Unknown

9,430 (27.4)

Hormonal Therapy

No

20,214 (58.7)

Yes

14,230 (41.3)

Immunotherapy

No

34,293 (99.6)

Yes

60 (0.2)

Unknown

91 (0.3)

Radiation

No

11,900 (34.5)

Yes

22,544 (65.5)